Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx
Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ:RARE) into potential breaches of fiduciary duty by the Company’s Board
of Directors (the “Board”).
Ultragenyx, headquartered in Novato, CA, is a clinical-stage, biopharmaceutical company focused on the treatment of genetic
diseases. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which
significantly diminish shareholder value and do not benefit the Company. Considering the Company’s lackluster performance since its
2014 initial public offering, it is clear that the Board lacks the ability to fairly assess and oversee the Company’s direction and
leadership.
Current Ultragenyx stockholders seeking more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Roger Sachar, Jr. (rsachar@nfllp.com) to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more
information, please visit the firm website at www.nfllp.com.
Newman Ferrara LLP
Jeffrey M. Norton, 212-619-5400
jnorton@nfllp.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170515006541/en/